Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
2(22%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_2
5
56%
Ph not_applicable
1
11%
Ph phase_1
2
22%
Ph phase_3
1
11%

Phase Distribution

2

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
5(55.6%)
Phase 3Large-scale testing
1(11.1%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(5)
Other(2)

Detailed Status

Completed5
Recruiting1
Active, not recruiting1
unknown1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (22.2%)
Phase 25 (55.6%)
Phase 31 (11.1%)
N/A1 (11.1%)

Trials by Status

recruiting111%
active_not_recruiting111%
unknown111%
completed556%
suspended111%

Recent Activity

2 active trials
Showing 5 of 9
completednot_applicable

High-Dose Ambroxol in Pediatric Type III Gaucher Disease (GD3)

NCT07285369
recruitingphase_2

Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial

NCT04588285
active_not_recruitingphase_2

Ambroxol as a Treatment for Parkinson's Disease Dementia

NCT02914366
unknownphase_2

A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS

NCT05959850
completedphase_2

Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy

NCT03950050
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07285369Not Applicable

High-Dose Ambroxol in Pediatric Type III Gaucher Disease (GD3)

Completed
NCT04588285Phase 2

Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial

Recruiting
NCT02914366Phase 2

Ambroxol as a Treatment for Parkinson's Disease Dementia

Active Not Recruiting
NCT05959850Phase 2

A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS

Unknown
NCT03950050Phase 2

Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy

Completed
NCT02941822Phase 2

Ambroxol in Disease Modification in Parkinson Disease

Completed
NCT00525044Phase 3

Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore Throat

Completed
NCT01463215Phase 1

Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease

Suspended
NCT01573663Phase 1

A Drug-Drug Interaction Study of Ambroxol and Levodropropizine

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9